Researchers identify two groups of antigen-presenting fibroblasts that support survival and growth of malignant tumors

Targeted radiation during surgery reduces pancreatic cancer recurrence, Hopkins study finds

Using intraoperative radiation to eliminate pancreatic cancer cells that have spread to areas around the pancreas, investigators at Johns Hopkins have been able to reduce the recurrence rate around the pancreas to 5%.

October 31, 2025

Vol.51 No.40

Cancer Policy

Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA

Earlier this year, FDA announced that it would be initiating a voucher program aimed at accelerating review time for applications that are deemed to be advancing U.S. “national priorities” (The Cancer Letter, June 20, 2025).

October 24, 2025

Vol.51 No.39

By Claire Marie Porter

Clinical Roundup

Zanzalintinib + atezolizumab improve survival in advanced CRC

Combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor, helped patients with metastatic colorectal cancer live longer and control their disease better than with the standard treatment drug regorafenib, according to a study led by UCLA investigators.

October 24, 2025

Vol.51 No.39

Clinical Roundup

UCSD researchers engineer novel antibody that triggers anti-tumor response

Researchers at the UC San Diego School of Medicine engineered a new anti-αvβ3 antibody that activates macrophages—a type of immune cell already abundant in advanced αvβ3+ tumors—and were able to trigger anti-tumor responses in both patient tumor samples and in mouse models.

October 17, 2025

Vol.51 No.38

Clinical Roundup

Kidney cancer drug shows promise against calcium imbalance caused by tumors, UTSW study shows

Elevated calcium levels in the blood—a complication of kidney cancers known as hypercalcemia—may be successfully treated with HIF-2α inhibitors developed by UT Southwestern Medical Center.

October 17, 2025

Vol.51 No.38

Clinical Roundup

Nanoparticle vaccine prevents melanoma, pancreatic, and breast cancers in mice, study finds

A study led by University of Massachusetts Amherst researchers demonstrates that their nanoparticle-based vaccine can effectively prevent melanoma, pancreatic, and triple-negative breast cancer in mice.

October 17, 2025

Vol.51 No.38

Researchers identify two groups of antigen-presenting fibroblasts that support survival and growth of malignant tumors

YOU MAY BE INTERESTED IN

Targeted radiation during surgery reduces pancreatic cancer recurrence, Hopkins study finds

Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA

Zanzalintinib + atezolizumab improve survival in advanced CRC

UCSD researchers engineer novel antibody that triggers anti-tumor response

Kidney cancer drug shows promise against calcium imbalance caused by tumors, UTSW study shows

Nanoparticle vaccine prevents melanoma, pancreatic, and breast cancers in mice, study finds

Renew today!

Subscriber content

Never miss an issue!

Login